Literature DB >> 16155191

Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.

D G R Evans1, J M Birch, R T Ramsden, S Sharif, M E Baser.   

Abstract

In recent years the use of radiation treatment for benign tumours has increased with the advent of stereotactic delivery and, in particular, single high dose gamma knife therapy. This has been particularly true for benign CNS (central nervous system) tumours such as vestibular schwannoma, meningioma, pituitary adenoma, and haemangioblastoma. While short term follow up in patients with isolated tumours suggests this treatment is safe, there are particular concerns regarding its use in childhood and in tumour predisposing syndromes. We have reviewed the use of radiation treatment in these contexts with particular regard to malignant transformation and new tumour induction. This review indicates that much more caution is warranted regarding the use of radiation treatment for benign tumours in childhood and in tumour prone conditions such as the neurofibromatoses.

Entities:  

Mesh:

Year:  2005        PMID: 16155191      PMCID: PMC2563223          DOI: 10.1136/jmg.2005.036319

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  77 in total

1.  Fibroblasts from Li-Fraumeni patients are resistant to low dose-rate irradiation.

Authors:  A R Sproston; J M Boyle; J Heighway; J M Birch; D Scott
Journal:  Int J Radiat Biol       Date:  1996-08       Impact factor: 2.694

2.  Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases.

Authors:  B S Ducatman; B W Scheithauer; D G Piepgras; H M Reiman; D M Ilstrup
Journal:  Cancer       Date:  1986-05-15       Impact factor: 6.860

3.  Radiation therapy of pituitary adenoma: delayed sequelae.

Authors:  B J Fisher; L E Gaspar; B Noone
Journal:  Radiology       Date:  1993-06       Impact factor: 11.105

4.  Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.

Authors:  M Brada; D Ford; S Ashley; J M Bliss; S Crowley; M Mason; B Rajan; D Traish
Journal:  BMJ       Date:  1992-05-23

5.  Brain tumours and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin syndrome.

Authors:  D G Evans; J M Birch; C I Orton
Journal:  Br J Neurosurg       Date:  1991       Impact factor: 1.596

6.  Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee.

Authors:  R Heyn; V Haeberlen; W A Newton; A H Ragab; R B Raney; M Tefft; M Wharam; L G Ensign; H M Maurer
Journal:  J Clin Oncol       Date:  1993-02       Impact factor: 44.544

7.  Multiple schwannomas and meningiomas associated with irradiation in childhood.

Authors:  L Sznajder; C Abrahams; D M Parry; T C Gierlowski; E Shore-Freedman; A B Schneider
Journal:  Arch Intern Med       Date:  1996-09-09

8.  Breast and other cancers in families with ataxia-telangiectasia.

Authors:  M Swift; P J Reitnauer; D Morrell; C L Chase
Journal:  N Engl J Med       Date:  1987-05-21       Impact factor: 91.245

9.  Incidence of second primary tumours among childhood cancer survivors.

Authors:  M M Hawkins; G J Draper; J E Kingston
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

10.  Second primary neoplasms in patients with retinoblastoma.

Authors:  G J Draper; B M Sanders; J E Kingston
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

View more
  77 in total

Review 1.  Exposing the thyroid to radiation: a review of its current extent, risks, and implications.

Authors:  Bridget Sinnott; Elaine Ron; Arthur B Schneider
Journal:  Endocr Rev       Date:  2010-07-21       Impact factor: 19.871

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

3.  Is anti-inflammatory radiotherapy an effective treatment in trochanteritis?

Authors:  Izaskun Valduvieco; Albert Biete; Luis A Moreno; Xavier Gallart; Angels Rovirosa; Jordi Saez; Carlos Plana; Pilar Peris
Journal:  Br J Radiol       Date:  2016-11-25       Impact factor: 3.039

4.  Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.

Authors:  Scott R Plotkin; Jaishri O Blakeley; D Gareth Evans; C Oliver Hanemann; Theo J M Hulsebos; Kim Hunter-Schaedle; Ganjam V Kalpana; Bruce Korf; Ludwine Messiaen; Laura Papi; Nancy Ratner; Larry S Sherman; Miriam J Smith; Anat O Stemmer-Rachamimov; Jeremie Vitte; Marco Giovannini
Journal:  Am J Med Genet A       Date:  2013-02-07       Impact factor: 2.802

5.  Deficient expression of aldehyde dehydrogenase 1A1 is consistent with increased sensitivity of Gorlin syndrome patients to radiation carcinogenesis.

Authors:  Aaron T Wright; Thierry Magnaldo; Ryan L Sontag; Lindsey N Anderson; Natalie C Sadler; Paul D Piehowski; Yannick Gache; Thomas J Weber
Journal:  Mol Carcinog       Date:  2013-11-27       Impact factor: 4.784

6.  Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe.

Authors:  Melania Ester Mercado-Pimentel; Craig Miller; Daniela N Rolph; Edrick F Villalobos; Allison M Dunn; Prithvi M Mohan; Suzu Igarashi; Xiangdang Liu; Macken Yrun-Duffy; Neal K Patel; Cecilia M Read; Ross H Francis; Adelina Isabella Lane; Swaroop Murugesh; Abraham Jacob
Journal:  Otol Neurotol       Date:  2017-01       Impact factor: 2.311

7.  Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.

Authors:  Anh N Le; Joanna Harton; Heena Desai; Jacquelyn Powers; Kristin Zelley; Angela R Bradbury; Katherine L Nathanson; Payal D Shah; Abigail Doucette; Gary M Freedman; Peter Gabriel; Susan M Domchek; Suzanne P MacFarland; Kara N Maxwell
Journal:  Breast Cancer Res Treat       Date:  2020-04-03       Impact factor: 4.872

8.  Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Marc S Ballas; Krysten Brown; Annette O Nusbaum; Tsivia Hochman; Judith D Goldberg; Kevin M Koch; John G Golfinos; J Thomas Roland; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2012-07-27       Impact factor: 12.300

Review 9.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

10.  X-ray treatment to the face and neck in infancy leading to multiple pathologies in later life: a case report.

Authors:  Paul Dakin
Journal:  Cases J       Date:  2009-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.